7 research outputs found
Effects of Valsartan vs Amlodipin on renal function in salt loaded spontaneously hypertensive rats
No full textThe goal of this study was to compare the effects of valsartan and amlodipin on the systolic blood pressure and parameters specific
to the renal function in salt loaded spontaneously hypertensive rats (SHR). 32 male SHR were used at age of 20 weeks and body weight ranging between 265-300 g. From 8 weeks of age tab water was replaced with a solution of NaCl (1%) given ad libitum. Rats were divided into 2 groups: valsartan treated group SHRVAL (n=16) in which valsartan was given at a dose of 10 mg/kg b. w. and amlodipine treated group SHRAMLO (n=16) in which amlodipine was given at a dose of 5 mg/kg b. w. For a period of 12 weeks we have evaluated the effect of the investigated drugs on systolic blood pressure, body weight and renal function tests. In salt loaded rats amlodipine was more effective in reducing the systolic blood pressure in contrast to valsartan who had more pronounced effect on renal parameters most evident in proteinuria. Since both treatment groups have different mechanism of action a combination therapy may be beneficial in improving renal
function in SHR rats
Imitational modeling of the possible optimal strategies of the predator and prey behavior in the early stages of evolution named “Chase”
No full textA New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography
No full textBACKGROUND: A new simple, selective and accurate high-performance liquid chromatographic (HPLC) method utilising solid-phase extraction for the determination of pantoprazole in human plasma samples has been developed. AIM: The purpose of this paper was developing a new HPLC method suitable for the determination of pantoprazole in plasma samples, which enables simple and rapid isolation and concentration of the analysed drug.METHODS: The chromatographic separation was accomplished on a LiChroCart LiChrospher 60 RP select B column using a mobile phase composed of 0.2 % (V/V) water solution of triethylamine (pH 7) and acetonitrile (58:42, V/V) followed by UV detection was at 280 nm. The solid-phase extraction method using LiChrolut RP-18 (200 mg, 3 ml) was applied to the obtained good separation of investigated drug from endogenous plasma components. Best results were achieved when plasma samples were buffered with 0.1 mol/L KH2PO4 (pH 9) before extraction, eluted and reconstituted with acetonitrile and 0.001 mol/L NaOH after extraction, respectively. RESULTS: The standard calibration curves showed good linearity within the range of 25.0-4000.0 ng/mL with a correlation coefficient greater than 0.996. Retention times of pantoprazole and internal standard, lansoprazole was 4.1 and 6.0 min respectively. The limit of quantification was 25.0 ng/mL. For intra- and inter-day precision relative standard deviations ranged from 4.2 to 9.3%. The relative errors for stability investigations were ranged from 0.12 to -10.5%. CONCLUSION: This method has good precision and accuracy and was successfully applied to the pharmacokinetic and bioequivalence study of 40 mg pantoprazole in healthy volunteers
Efektite na prostaciklin vo tretmanot na dijabeticnata nefropatija kaj staorci
No full textMikrovaskularnite komplikacii, a pred se dijabeticnata nefropatija, se edni od najteskite komplikacii na dijabetot, od koi vo golema mera zavisi i prognozata na dijabetot kaj ovie pacienti. Etiopatogenezata na ovaa komplikacija e multifaktorijalna i za sega se uste ne kompletno rasvetlena, a vklucuva morfoloski, patolosko-anatomski i biohemiski metabolni narusuvanja. Se smeta deka narusuvanjeto na modularnata funkcija na endoteliumot
moze da bide kriticen i inicijalen faktor vo razvojot na dijabeticnite vaskularni komplikacii. Vrz osnova na farmakodinamskite efekti koi sto gi poseduva prostaciklinot (PGI2) i negovite analozi, se smeta deka istite moze da bidat korisni vo tretmanot na dijabeti~nata nefropatija.
Osnovna cel na ovaa studija be{e da se procenat efektite na prostaciklin (PGI2) vo tretmanot na dijabeticnata
nefropatija, eksperimentalno predizvikana so streptozocin.
Kaj normotenzivni staorci od sojot Wistar, eksperimentalno bese induciran najprvin dijabet so ednokratna i.p. administracija na streptozocin (STZ), a kako komplikacija na dijabetot i jasni znaci i simptomi na dijabeticna nefropatija (proteinurija, zgolemeno serumsko nivo na urea i kreatinin, poliurija, zgolemena aktivnost na NAG vo mockata). Tretman so prostaciklin (p.o.) vo doza od 0.1 mg/kg /t.t./den, vo tekot na 4 nedeli, dovede do signifikantno
namaluvanje na simptomite i znacite na bubreznite ostetuvanja, vo odnos na grupata zivotni koi ne primaa prostaciklin.
Vrz osnova na dobienite rezultati moze da se zakluci deka prostaciklinot moze da ima znacajna uloga vo tretmanot
na dijabeticnata nefropatija, eksperimentalno inducirana so streptozocin
Ulogata na endoetelin-1 vo razvojot na dijabeticna nefropatija inducirana so streptozocin
No full textDijabeticnata nefropatija pretstavuva edna od hronicnite mikrovaskularni komplikacii na dijabetot, so multifaktorijalna
i ne do kraj rasvetlena etiopatogeneza. So ogled na toa sto kaj pacientite so dijabet, osobeno kaj onie so dijabeticna nefropatija, se najdeni zgolemeni vrednosti na endotelin-1, se pretpostavuva deka istiot moze da ima znacajna uloga vo razvojot na dijabeticnata nefropatija.
Osnovna cel na nasata studija bese da se detektiraat promenite vo plazmatskoto nivo na endotelin-1 po eksperimentalno
induciran dijabet, i dijabeticna nefropatija kaj staorci so streptozocin. So ogled na dobro poznatite efekti na AKE-inhibitorite, vo ovaa studija go ispituvavme i vlijanieto na enalapril (AKE inhibitor) na plazmatskite koncentracii na endotelin-1, kako i negovite efekti vo tretmanot na dijabeti~na nefropatija. Ednokratnata i.p. administracija na streptozocin (STZ) predizvika signifikantno zgolemuvanje na plazmatskite koncentracii
na endotelin-1, proprateni so jasno izrazeni simptomi i znaci na dijabeticna nefropatija (mikroalbuminurija, zgolemeni urinarni vrednosti na N-acetyl-fl-D-glucosamidase, zgolemeni serumski koncentracii na urea, poliurija).
Cetiri nedelniot tretman so enalapril dovede do signifikantno namaluvanje na plazmatskite koncentracii na endotelin-1 i do podobruvanje na simtomite i znacite na dijabeticnata nefropatija. Dobienite rezultati potvrduvaat deka endotelin-1 moze da ima znacajna uloga vo razvojot i progresijata na dijabeticnata nefropatija, a AKE inhibitorite, odnosno enalapril, mozat da ja ublazat i usporat progresijata na dijabeticnata nefropatij
Epoetin alfa ja namaluva nefrotoksicnosta inducirana so cisplatin kaj staorci
No full textKlinickata efikasnost na cisplatin kako antitumorski lek e nesomnena, no dozno-limitiracki faktor za negova
upotreba pretstavuva izrazitata nefrotoksicnost. Najnovite istrazuvawa pokazuvaat deka epoetin alfa moze da ima znacajna uloga ne samo vo terapiski celi za korekcija na razni vidovi na anemii, tuku istiot moze da bide efikasen i kako nevroprotektiv, hepatoprotektiv, kardioprotektiv i osobeno znacajno kako nefroprotektiv kaj nefrotoksicnost inducirana od preparati na baza na platina.
Glavna cel na ovaa studija bese da se utvrdi efektot na epoetin alfa vo prevencijata na nefrotoksicnost eksperimentalno inducirana so dolgotrajna administracija na cisplatin vo doza od 2 mg/kg/t.t./nedela vo tek na 8 nedeli, kaj Wistar staorci. Dobienite rezultati od ovaa studija pokazuvaat deka epoetin alfa signifikantno gi ublazuva funkcionalnite bubrezni poremetuvawa inducirani so dolgotrajna administracija na cisplatin, ja
podobruva opstata sostojba i go namaluva mortalitetot kaj ispituvanite zivotni
Efekti na amifostin vo prevencija na nefrotoksicnost inducirana so cisplatin kaj staorci
No full textAmifostin e relativno nov organski citoprotektiven lek, koj vsusnost pretstavuva prolek, namenet za namaluvanje
na kumulativnata renalna toksicnost inducirana od povtoruvana administracija na cisplatin. Mehanizmot
na nefroprotektivnoto dejstvo na amifostin ne e kompletno razjasnet, no se smeta deka lekot poseduva direktno
citoprotektivno dejstvo na bubreznite tubuli.
Osnovnata cel na ovaa studija bese da se utvrdi efektot na amifostin vo prevencijata na nefrotoksicnost eksperimentalno
inducirana so dolgotrajna administracija na cisplatin vo doza od 2 mg/kg/t.t./nedela vo tek na 8 nedeli.
Dobienite rezultati od ovaa studija pokazuvaat deka amifostin, iako ne kompletno, vo golema mera ja reducira
nefrotoksicnosta inducirana so dolgotrajna administracija na cisplatin
